Enrollment initiated in Ph 2 Trial of Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma September 7, 2022
Ph 2 SCOPE trial of SCIB1 vaccine in metastatic melanoma patients expanded; additional cohort to test SCIB1 vaccine in combination with checkpoint doublet therapy June 16, 2022
